LABCORP HOLDINGS INC. (LH) Spending and interest coverage
- R&D / revenue · 12 months: Value (m); Formula and calculation Research and development expense / revenue. Period ending 2026-06-30..
- Stock-based compensation / revenue · 12 months: Value 0.87%; Formula and calculation Share-based compensation / revenue. Period ending 2026-06-30..
- Interest coverage · 12 months: Value 6.59×; Formula and calculation Operating income ÷ reported interest expense..
Spending and interest coverage
Overview →Financial period ending 2026-06-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| R&D / revenue · 12 months | (m) | Research and development expense / revenue. Period ending 2026-06-30. Calculation unavailable: missing inputs remain (m). |
| Stock-based compensation / revenue · 12 months | 0.87% | Share-based compensation / revenue. Period ending 2026-06-30. $125.50M ÷ $14.35B × 100 ≈ 0.87% |
| Interest coverage · 12 months | 6.59× | Operating income ÷ reported interest expense. $1.50B ÷ $227.20M ≈ 6.59× |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Research and development spending | (m) | Research and Development Expense |
| Revenue | 14.35B USD | |
| Stock-based compensation | 125.50M USD | Share-based Payment Arrangement, Noncash Expense |
| Operating income | 1.50B USD | Operating Income (Loss) |
| Interest expense · reported / estimated | 227.20M USD | Interest Expense · Estimated expense assumptions |
Latest interest expense basis: Reported. Estimated values carry *; expand each history row’s basis for its dated balances and rate assumptions.
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Research and development spending (USD) | Revenue (USD) | Stock-based compensation (USD) | Operating income (USD) | Interest expense · reported / estimated (USD) | R&D / revenue | SBC / revenue | Interest coverage | Interest expense basis |
|---|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | (m) | $14.35B | $125.50M | $1.50B | $227.20M | (m) | 0.87% | 6.59× | Reported |
| 2026-03-31 | (m) | $14.14B | $124.70M | $1.44B | $223.20M | (m) | 0.88% | 6.45× | Reported |
| 2025-12-31 | (m) | $13.95B | $125.80M | $1.38B | $224.10M | (m) | 0.90% | 6.18× | Reported |
| 2025-09-30 | (m) | $13.77B | $123.40M | $1.33B | $232.50M | (m) | 0.90% | 5.74× | Reported |
| 2025-06-30 | (m) | $13.48B | $121.20M | $1.19B | $226.90M | (m) | 0.90% | 5.25× | Reported |
| 2025-03-31 | (m) | $13.18B | $117.90M | $1.09B | $217.40M | (m) | 0.89% | 5.02× | Reported |
| 2024-12-31 | (m) | $13.01B | $116.70M | $1.09B | $208.30M | (m) | 0.90% | 5.22× | Reported |
| 2024-09-30 | (m) | $12.71B | $116.40M | $747.40M | $193.70M | (m) | 0.92% | 3.86× | Reported |
| 2024-06-30 | (m) | $12.49B | $123.80M | $745.60M | $193.60M | (m) | 0.99% | 3.85× | Reported |
| 2024-03-31 | (m) | $12.30B | $127.40M | $717.10M | $195.80M | (m) | 1.04% | 3.66× | Reported |
| 2023-12-31 | (m) | $12.16B | $128.70M | $725.60M | $199.60M | (m) | 1.06% | 3.64× | Reported |
| 2023-09-30 | (m) | $15.07B | $152.60M | $1.21B | $200.40M | (m) | 1.01% | 6.06× | Reported |
| 2023-06-30 | (m) | $14.88B | $147.70M | $1.34B | $196.40M | (m) | 0.99% | 6.80× | Reported |
| 2023-03-31 | (m) | $14.76B | $146.50M | $1.43B | $188.80M | (m) | 0.99% | 7.56× | Reported |
| 2022-12-31 | (m) | $14.88B | $144.10M | $1.77B | $180.30M | (m) | 0.97% | 9.84× | Reported |
| 2022-09-30 | (m) | $15.26B | $156.00M | $2.41B | $174.10M | (m) | 1.02% | 13.86× | Reported |
| 2022-06-30 | (m) | $15.72B | $178.70M | $2.71B | $170.00M | (m) | 1.14% | 15.95× | Reported |
| 2022-03-31 | (m) | $15.86B | $163.20M | $2.89B | $205.80M | (m) | 1.03% | 14.04× | Reported |
| 2021-12-31 | (m) | $16.12B | $153.70M | $3.26B | $212.10M | (m) | 0.95% | 15.37× | Reported |
| 2021-09-30 | (m) | $16.55B | $138.40M | $3.82B | $217.30M | (m) | 0.84% | 17.59× | Reported |
| 2021-06-30 | (m) | $16.39B | $106.60M | $4.10B | $226.50M | (m) | 0.65% | 18.11× | Reported |
| 2021-03-31 | (m) | $15.32B | $122.50M | $3.70B | $200.90M | (m) | 0.80% | 18.40× | Reported |
| 2020-12-31 | (m) | $13.98B | $111.70M | $2.45B | $207.40M | (m) | 0.80% | 11.79× | Reported |
| 2020-09-30 | (m) | $12.44B | $108.40M | $1.49B | $223.50M | (m) | 0.87% | 6.66× | Reported |
| 2020-06-30 | (m) | $11.47B | $112.70M | $781.40M | $232.60M | (m) | 0.98% | 3.36× | Reported |
| 2020-03-31 | (m) | $11.59B | $99.40M | $819.40M | $239.00M | (m) | 0.86% | 3.43× | Reported |
| 2019-12-31 | (m) | $11.55B | $107.00M | $1.33B | $240.70M | (m) | 0.93% | 5.53× | Reported |
| 2019-09-30 | (m) | $11.39B | $104.30M | $1.30B | $234.50M | (m) | 0.92% | 5.55× | Reported |
| 2019-06-30 | (m) | $11.29B | $91.60M | $1.30B | $233.40M | (m) | 0.81% | 5.59× | Reported |
| 2019-03-31 | (m) | $11.28B | $91.30M | $1.34B | $237.40M | (m) | 0.81% | 5.64× | Reported |
| 2018-12-31 | (m) | $11.33B | $91.60M | $1.33B | $244.20M | (m) | 0.81% | 5.43× | Reported |
| 2018-09-30 | (m) | (m) | $94.70M | $1.41B | $253.80M | (m) | (m) | 5.55× | Reported |
| 2018-06-30 | (m) | (m) | $109.00M | $1.39B | $254.30M | (m) | (m) | 5.47× | Reported |
| 2018-03-31 | (m) | (m) | $107.80M | $1.35B | $246.20M | (m) | (m) | 5.49× | Reported |
| 2017-12-31 | (m) | (m) | $109.70M | $1.36B | $235.10M | (m) | (m) | 5.80× | Reported |
| 2017-09-30 | (m) | (m) | $113.50M | $1.33B | $220.20M | (m) | (m) | 6.06× | Reported |
| 2017-06-30 | (m) | (m) | $104.70M | $1.32B | $218.50M | (m) | (m) | 6.02× | Reported |
| 2017-03-31 | (m) | (m) | $105.50M | $1.35B | $217.00M | (m) | (m) | 6.20× | Reported |
| 2016-12-31 | (m) | (m) | $109.60M | $1.31B | $219.10M | (m) | (m) | 5.99× | Reported |
| 2016-09-30 | (m) | (m) | $106.30M | $1.23B | $223.00M | (m) | (m) | 5.52× | Reported |
| 2016-06-30 | (m) | (m) | $105.70M | $1.22B | $220.70M | (m) | (m) | 5.51× | Reported |
| 2016-03-31 | (m) | (m) | $107.60M | $1.17B | $225.10M | (m) | (m) | 5.21× | Reported |
| 2015-12-31 | (m) | (m) | $102.10M | $1.00B | $274.90M | (m) | (m) | 3.65× | Reported |
| 2015-09-30 | (m) | (m) | $88.30M | $978.50M | $250.20M | (m) | (m) | 3.91× | Reported |
| 2015-06-30 | (m) | (m) | $76.10M | $912.80M | $220.20M | (m) | (m) | 4.15× | Reported |
| 2015-03-31 | (m) | (m) | $60.30M | $837.30M | $188.10M | (m) | (m) | 4.45× | Reported |
| 2014-12-31 | (m) | $6.01B | $45.70M | $910.40M | $109.50M | (m) | 0.76% | 8.31× | Reported |
| 2014-09-30 | (m) | $5.94B | $43.50M | $906.40M | $101.60M | (m) | 0.73% | 8.92× | Reported |
| 2014-06-30 | (m) | $5.85B | $38.80M | $909.60M | $100.40M | (m) | 0.66% | 9.06× | Reported |
| 2014-03-31 | (m) | $5.80B | $37.70M | $932.20M | $97.70M | (m) | 0.65% | 9.54× | Reported |
| 2013-12-31 | (m) | $5.81B | $37.30M | $990.90M | $96.50M | (m) | 0.64% | 10.27× | Reported |
| 2013-09-30 | (m) | $5.78B | $34.80M | $991.20M | $99.90M | (m) | 0.60% | 9.92× | Reported |
| 2013-06-30 | (m) | $5.73B | $39.10M | $991.70M | $99.30M | (m) | 0.68% | 9.99× | Reported |
| 2013-03-31 | (m) | $5.69B | $40.20M | $998.40M | $97.50M | (m) | 0.71% | 10.24× | Reported |
| 2012-12-31 | (m) | $5.67B | $40.70M | $1.02B | $94.50M | (m) | 0.72% | 10.83× | Reported |
| 2012-09-30 | (m) | $5.63B | $46.50M | $1.06B | $89.10M | (m) | 0.83% | 11.85× | Reported |
| 2012-06-30 | (m) | $5.62B | $47.10M | $1.05B | $85.30M | (m) | 0.84% | 12.31× | Reported |
| 2012-03-31 | (m) | $5.60B | $47.60M | $999.70M | $85.00M | (m) | 0.85% | 11.76× | Reported |
| 2011-12-31 | (m) | $5.54B | $48.90M | $948.40M | $87.50M | (m) | 0.88% | 10.84× | Reported |
| 2011-09-30 | (m) | $5.47B | $47.70M | $939.70M | $-84.60M | (m) | 0.87% | (m) | Reported |
| 2011-06-30 | (m) | $5.34B | $46.10M | $935.60M | $-85.90M | (m) | 0.86% | (m) | Reported |
| 2011-03-31 | (m) | $5.18B | $44.40M | $980.40M | $-79.40M | (m) | 0.86% | (m) | Reported |
| 2010-12-31 | (m) | $5.00B | $40.00M | $978.80M | $-70.00M | (m) | 0.80% | (m) | Reported |
| 2010-09-30 | (m) | $4.87B | $39.80M | $955.80M | $-65.40M | (m) | 0.82% | (m) | Reported |
| 2010-06-30 | (m) | $4.78B | $39.00M | $955.40M | $-58.80M | (m) | 0.82% | (m) | Reported |
| 2010-03-31 | (m) | $4.73B | $37.90M | $929.60M | $-60.50M | (m) | 0.80% | (m) | Reported |
| 2009-12-31 | (m) | $4.69B | $36.40M | $935.90M | $-62.90M | (m) | 0.78% | (m) | Reported |
| 2009-09-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2009-06-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2009-03-31 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2008-12-31 | (m) | $4.51B | $36.20M | $842.90M | $-72.00M | (m) | 0.80% | (m) | Reported |
| 2008-09-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2008-06-30 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2007-12-31 | (m) | $4.07B | $35.40M | $777.00M | $-56.60M | (m) | 0.87% | (m) | Reported |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| QUEST DIAGNOSTICS INC (DGX) | United States | $26.096B | 22.09 |
| Guardant Health, Inc. (GH) | United States | $23.675B | -12.65 |
| Caris Life Sciences, Inc. (CAI) | United States | $9.119B | 47.87 |
| RadNet, Inc. (RDNT) | United States | $5.611B | -229.65 |
| GRAIL, Inc. (GRAL) | United States | $5.591B | -7.78 |
| VERACYTE, INC. (VCYT) | United States | $3.904B | 41.21 |
| Celcuity Inc. (CELC) | United States | $3.887B | -22.62 |
| CareDx, Inc. (CDNA) | United States | $3.174B | 13.21 |
| Fortrea Holdings Inc. (FTRE) | United States | $1.903B | -19.43 |
| Personalis, Inc. (PSNL) | United States | $1.769B | -13.30 |